On August 29, 2019 Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, reported that Kitov’s subsidiary, TyrNovo, will present new data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Pancreatic Cancer: Advances in Science and Clinical Care conference being held September 6 – 9, 2019 in Boston (Press release, Kitov Pharmaceuticals , AUG 29, 2019, View Source [SID1234539103]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will showcase new data on NT-219, Kitov’s developmental first-in-class, small molecule, dual inhibitor of the two common cancer resistance pathways STAT3 and IRS1/2. Kitov is advancing NT-219 primarily for the treatment of recurrent and metastatic squamous cell carcinoma of head & neck cancer (SCCHN) and exploring its potential in additional oncology indications including pancreatic cancer.
Presentation Details:
Title: NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2 Sensitized Resistant Pancreatic Tumors to Gemcitabine and MEK inhibitor and Induced Tumor Regression
Session: Poster session C
Presenter: Hadas Reuveni, Ph.D.
Date: September 8, 2019
Time: 4:00 p.m. – 6:30 p.m. ET
Location: Westin Copley Place, Boston, MA
About the AACR (Free AACR Whitepaper) Pancreatic Cancer: Advances in Science and Clinical Care Conference
The conference will be the sixth AACR (Free AACR Whitepaper) Special Conference on pancreatic cancer. According to the U.S. National Cancer Institute, pancreatic cancer will account for approximately 44,330 deaths in 2018 and is poised to become the third leading cause of cancer deaths by 2030. As the field continues to grow, it is imperative that researchers can interact, share data, and discuss ideas to help reach the overall goal of improved treatment for pancreatic cancer. The conference will showcase sessions on tumor heterogeneity, immunology, prevention and early detection, and novel treatment combinations, among others.